Search - tctmd.com

Displaying 121 - 140 of 555

Sort: Relevancy | Date

Presentation TCT 2017

ABSORB II 4-Year, ABSORB III 3-Year, ABSORB IV 30-Day: Highlights Summary

Presenter: Martin B. Leon, Marco Valgimigli, Gregg W. Stone

November 01, 2017

Presentation TCT 2017

Bioresorbable Scaffolds and Stents: From PROSPECT-ABSORB to PREVENT (With Case Examples)

Presenter: Gregg W. Stone, Peter H. Stone, Jung-Min Ahn

November 01, 2017

Presentation TCT 2017

Do Some, All, or None of the Outcomes With the First Generation Absorb Scaffold Imply a Class Effect for All BRS? Educated Insights

Presenter: Bernard R. Chevalier, Corrado Tamburino, Yoshinobu Onuma

October 31, 2017

Presentation TCT 2017

Debate: With Improved Technology and Optimal Technique ABSORB Will Become a Widely Used Device

Presenter: Stephen G. Ellis, Takeshi Kimura, Hiram G. Bezerra

October 31, 2017

Presentation TCT 2017

Debate: ABSORB Is Likely Finished - The Limitation of the Technology Can Not Be Overcome

Presenter: Stephen G. Ellis, Takeshi Kimura, Robert A. Byrne

October 31, 2017

Presentation TCT 2017

The Potential For BRS: What Weve Learned From Pushing The Envelope

Presenter: Stephen G. Ellis, Takeshi Kimura, Corrado Tamburino

October 31, 2017

Presentation TCT 2017

Registry Update: ABSORB SCAAR

Presenter: Stephen G. Ellis, Takeshi Kimura, Stefan K. James

October 31, 2017

Presentation TCT 2017

Registry Update: BVS STEMI STRATEGY

Presenter: Stephen G. Ellis, Takeshi Kimura, Alfonso Ielasi

October 31, 2017

Presentation TCT 2017

Registry Update: IT-DISAPPEARS

Presenter: Stephen G. Ellis, Takeshi Kimura, Francesco Bedogni

October 31, 2017

Presentation TCT 2017

Registry Update: FRANCE ABSORB

Presenter: Stephen G. Ellis, Takeshi Kimura, Didier Carrié

October 31, 2017

Presentation TCT 2017

Registry Update: GABI-R

Presenter: Stephen G. Ellis, Takeshi Kimura, Holger M. Nef

October 31, 2017

Presentation TCT 2017

Registry Update: ABSORB UK

Presenter: Stephen G. Ellis, Takeshi Kimura, Mark A. de Belder

October 31, 2017

Presentation TCT 2017

Registry Update: ABSORB Extend At 3 Years

Presenter: Stephen G. Ellis, Takeshi Kimura, Antonio L. Bartorelli

October 31, 2017

Presentation TCT 2017

What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis

Presenter: Azeem Latib, Gregg W. Stone

October 31, 2017

Presentation TCT 2017

ABSORB IV 30-Day Results: Is Improved Technique Reflected in Superior Early Outcomes?

Presenter: Azeem Latib, Dean J. Kereiakes

October 31, 2017

Presentation TCT 2017

Featured Lecture: ABSORB Program 3-Year Meta-Analysis and Adjusted PSP Evaluation - Lessons Learned With a First Generation Scaffold

Presenter: Azeem Latib, Gregg W. Stone

October 31, 2017

Presentation TCT 2017

ABSORB II at 4 Years: Clinical Outcomes Beyond the Cusp of Complete Bioresorption

Presenter: Azeem Latib, Bernard R. Chevalier

October 31, 2017

Presentation TCT 2017

ABSORB in STEMI I: TROFI II 3-Year Clinical Outcomes and Correlations With the 6-Month OCT Findings

Presenter: Azeem Latib, Manel Sabate

October 31, 2017

Presentation TCT 2017

New Insights From AIDA: Subgroups and Predictors of Adverse Events

Presenter: Azeem Latib, Joanna J. Wykrzykowska

October 31, 2017

Presentation TCT 2017

TCT 14: Safety and Clinical Performance of the Drug-Eluting Absorbable Metal Scaffold in the Treatment of Subjects With De Novo Lesions in Native Coronary Arteries at 12-Month Follow-up - BIOSOLVE-II and BIOSOLVE-III

Presenter: Stephan Achenbach, Jacques J. Koolen, Ron Waksman

October 31, 2017

Advertisement

ABSORB II 4-Year, ABSORB III 3-Year, ABSORB IV 30-Day: Highlights Summary

Bioresorbable Scaffolds and Stents: From PROSPECT-ABSORB to PREVENT (With Case Examples)

Do Some, All, or None of the Outcomes With the First Generation Absorb Scaffold Imply a Class Effect for All BRS? Educated Insights

Debate: With Improved Technology and Optimal Technique ABSORB Will Become a Widely Used Device

Debate: ABSORB Is Likely Finished - The Limitation of the Technology Can Not Be Overcome

The Potential For BRS: What Weve Learned From Pushing The Envelope

Registry Update: ABSORB SCAAR

Registry Update: BVS STEMI STRATEGY

Registry Update: IT-DISAPPEARS

Registry Update: FRANCE ABSORB

Registry Update: GABI-R

Registry Update: ABSORB UK

Registry Update: ABSORB Extend At 3 Years

What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis

ABSORB IV 30-Day Results: Is Improved Technique Reflected in Superior Early Outcomes?

Featured Lecture: ABSORB Program 3-Year Meta-Analysis and Adjusted PSP Evaluation - Lessons Learned With a First Generation Scaffold

ABSORB II at 4 Years: Clinical Outcomes Beyond the Cusp of Complete Bioresorption

ABSORB in STEMI I: TROFI II 3-Year Clinical Outcomes and Correlations With the 6-Month OCT Findings

New Insights From AIDA: Subgroups and Predictors of Adverse Events

TCT 14: Safety and Clinical Performance of the Drug-Eluting Absorbable Metal Scaffold in the Treatment of Subjects With De Novo Lesions in Native Coronary Arteries at 12-Month Follow-up - BIOSOLVE-II and BIOSOLVE-III

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content